Savvipharm Inc
Records under this name other than the patents Savvipharm Inc holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,750,018 | Use of carboxiamidotriazole (CAI) orotate in macular degeneration Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,148,339 | Method of reducing cardiac levels of doxorubicin when given as orotate salt Term ended Term ended Jul 31, 2026 · From the USPTO record | Term ended | Term ended Jul 31, 2026 | From the USPTO record |
| US 8,802,831 | Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt Term ended Ended no later than Jul 31, 2026 · From the USPTO record | Term ended | Ended no later than Jul 31, 2026 | From the USPTO record |
| US 8,034,823 | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts Formerly held Term ended Term ended Feb 19, 2026 · From the USPTO record | Term ended | Term ended Feb 19, 2026 | From the USPTO record |
| US 8,415,388 | Pharmaceutical compositions containing paclitaxel orotate Term ended Term ended Sep 17, 2025 · From the USPTO record | Term ended | Term ended Sep 17, 2025 | From the USPTO record |
| US 7,601,834 | Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives Term ended Term ended Aug 24, 2025 · From the USPTO record | Term ended | Term ended Aug 24, 2025 | From the USPTO record |
| US 7,378,054 | Specimen collecting, processing and analytical assembly Term ended Term ended Oct 26, 2024 · From the USPTO record | Term ended | Term ended Oct 26, 2024 | From the USPTO record |
| US 6,184,227 | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases Formerly held Term ended Term ended Apr 20, 2019 · From the USPTO record | Term ended | Term ended Apr 20, 2019 | From the USPTO record |
| US 6,239,137 | Salts of aminoimidazole carboxamide and 5 amino or substituted amino 1,2,3-triazole, induce apoptosis, inhibit DNA synthesis and control cyclooxygenase activity Formerly held Term ended Term ended Jan 15, 2019 · From the USPTO record | Term ended | Term ended Jan 15, 2019 | From the USPTO record |
| US 5,728,707 | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide Formerly held Term ended Term ended no later than Mar 17, 2018 · Low confidence | Term ended | Term ended no later than Mar 17, 2018 | Low confidence |